Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Chemotherapy-induced Nausea and Vomiting
View Full LandscapeTarget Indication
Chemotherapy-induced Nausea and Vomiting
Clinical Trial
NCT00273468Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Sancuso
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
View on EMA